Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia.

Claiborne DT, Dudek TE, Maldini CR, Power KA, Ghebremichael M, Seung E, Mellors EF, Vrbanac VD, Krupp K, Bisesi A, Tager AM, Knipe DM, Boutwell CL, Allen TM.

J Virol. 2019 Sep 30;93(20). pii: e00814-19. doi: 10.1128/JVI.00814-19. Print 2019 Oct 15.

PMID:
31375576
2.

IL-21 induces antiviral microRNA-29 in CD4 T cells to limit HIV-1 infection.

Adoro S, Cubillos-Ruiz JR, Chen X, Deruaz M, Vrbanac VD, Song M, Park S, Murooka TT, Dudek TE, Luster AD, Tager AM, Streeck H, Bowman B, Walker BD, Kwon DS, Lazarevic V, Glimcher LH.

Nat Commun. 2015 Jun 25;6:7562. doi: 10.1038/ncomms8562.

3.

PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads.

Seung E, Dudek TE, Allen TM, Freeman GJ, Luster AD, Tager AM.

PLoS One. 2013 Oct 21;8(10):e77780. doi: 10.1371/journal.pone.0077780. eCollection 2013.

4.

HIV-specific CD8⁺ T-cell immunity in humanized bone marrow-liver-thymus mice.

Dudek TE, Allen TM.

J Infect Dis. 2013 Nov;208 Suppl 2:S150-4. doi: 10.1093/infdis/jit320. Review.

5.

BLT-humanized C57BL/6 Rag2-/-γc-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection.

Lavender KJ, Pang WW, Messer RJ, Duley AK, Race B, Phillips K, Scott D, Peterson KE, Chan CK, Dittmer U, Dudek T, Allen TM, Weissman IL, Hasenkrug KJ.

Blood. 2013 Dec 12;122(25):4013-20. doi: 10.1182/blood-2013-06-506949. Epub 2013 Sep 10. Erratum in: Blood. 2014 Sep 11;124(11):1848.

6.

Rapid evolution of HIV-1 to functional CD8⁺ T cell responses in humanized BLT mice.

Dudek TE, No DC, Seung E, Vrbanac VD, Fadda L, Bhoumik P, Boutwell CL, Power KA, Gladden AD, Battis L, Mellors EF, Tivey TR, Gao X, Altfeld M, Luster AD, Tager AM, Allen TM.

Sci Transl Med. 2012 Jul 18;4(143):143ra98. doi: 10.1126/scitranslmed.3003984.

7.

Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection.

Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, Berlin AM, Malboeuf CM, Ryan EM, Gnerre S, Zody MC, Erlich RL, Green LM, Berical A, Wang Y, Casali M, Streeck H, Bloom AK, Dudek T, Tully D, Newman R, Axten KL, Gladden AD, Battis L, Kemper M, Zeng Q, Shea TP, Gujja S, Zedlack C, Gasser O, Brander C, Hess C, Günthard HF, Brumme ZL, Brumme CJ, Bazner S, Rychert J, Tinsley JP, Mayer KH, Rosenberg E, Pereyra F, Levin JZ, Young SK, Jessen H, Altfeld M, Birren BW, Walker BD, Allen TM.

PLoS Pathog. 2012;8(3):e1002529. doi: 10.1371/journal.ppat.1002529. Epub 2012 Mar 8.

8.

Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.

Wheeler LA, Trifonova R, Vrbanac V, Basar E, McKernan S, Xu Z, Seung E, Deruaz M, Dudek T, Einarsson JI, Yang L, Allen TM, Luster AD, Tager AM, Dykxhoorn DM, Lieberman J.

J Clin Invest. 2011 Jun;121(6):2401-12. doi: 10.1172/JCI45876. Epub 2011 May 16.

9.

Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa.

Dudek TE, Torres-Lopez E, Crumpacker C, Knipe DM.

J Infect Dis. 2011 May 15;203(10):1434-41. doi: 10.1093/infdis/jir047. Epub 2011 Apr 14. Erratum in: J Infect Dis. 2011 Aug;204(3):492.

10.

Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein.

Reszka NJ, Dudek T, Knipe DM.

Vaccine. 2010 Mar 24;28(15):2754-62. doi: 10.1016/j.vaccine.2010.01.030. Epub 2010 Jan 29.

11.

Genetic engineering of a modified herpes simplex virus 1 vaccine vector.

Liu X, Broberg E, Watanabe D, Dudek T, Deluca N, Knipe DM.

Vaccine. 2009 May 11;27(21):2760-7. doi: 10.1016/j.vaccine.2009.03.003. Epub 2009 Mar 13.

12.

[Importance of different imaging methods in diagnosis of significant urodynamically uretropelvic junction obstruction in children with congenital hydronephrosis].

Krzemień G, Roszkowska-Blaim M, Szmigielska A, Kamińska A, Warchoł S, Dudek T.

Pol Merkur Lekarski. 2008;24 Suppl 4:41-5. Polish.

PMID:
18924501
13.

Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs.

Hoshino Y, Pesnicak L, Dowdell KC, Lacayo J, Dudek T, Knipe DM, Straus SE, Cohen JI.

Vaccine. 2008 Jul 29;26(32):4034-40. doi: 10.1016/j.vaccine.2008.05.022. Epub 2008 Jun 2.

15.

Helminth infection suppresses T-cell immune response to HIV-DNA-based vaccine in mice.

Da'Dara AA, Lautsch N, Dudek T, Novitsky V, Lee TH, Essex M, Harn DA.

Vaccine. 2006 Jun 12;24(24):5211-9. Epub 2006 Apr 18.

PMID:
16675073
16.

Replication-defective viruses as vaccines and vaccine vectors.

Dudek T, Knipe DM.

Virology. 2006 Jan 5;344(1):230-9. Review.

17.

Interaction between HIV type 1 glycoprotein 120 and CXCR4 coreceptor involves a highly conserved arginine residue in hypervariable region 3.

Wang WK, Lee CN, Dudek T, Chang SY, Zhao YJ, Essex M, Lee TH.

AIDS Res Hum Retroviruses. 2000 Nov 20;16(17):1821-9.

PMID:
11118068
18.
19.

CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120.

Wang WK, Dudek T, Zhao YJ, Brumblay HG, Essex M, Lee TH.

Proc Natl Acad Sci U S A. 1998 May 12;95(10):5740-5.

Supplemental Content

Support Center